151 results about "Glucose transporter" patented technology

The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.

The invention relates to compositions comprising three inhibitors, one pancreatic lipase inhibitor, an alpha glucosidase inhibitor, and a sodium dependent glucose transporter inhibitor. The invention also provides methods of using the compositions for controlling glucose and lipid uptake.

The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.

The invention relates to compositions comprising at least two inhibitors selected from the group consisting of an alpha amylase inhibitor, an alpha glucosidase inhibitor, and a sodium dependent glucose transporter inhibitor. The invention also provides methods of using the compositions for controlling glucose uptake.

The invention relates to a C-aryl glucoside derivative shown by a formula (I) or salts thereof acceptable in pharmacy or all stereoisomerides thereof, a preparation method thereof, a pharmaceutical composition containing the derivative, and the application of the derivative as a therapeutic agent, particularly as a SGLT (Sodium Dependent Glucose Transporter) inhibitor, wherein the definitions of each substituent group in the formula (I) are same with those in a specification.

Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.

The invention discloses a method for improving production of a lignocellulosic enzyme line from filamentous fungi and an application of the filamentous fungi in fermentation of microbial bio-based chemicals, and belongs to the field of genetic engineering. According to the method, high-affinity glucose transporter of the filamentous fungi is transformed by virtue of such genetic engineering approaches as knocking-out, mutation, importing and the like, and an obtained engineering strain has the advantages. The filamentous fungi include, but not limited in, neurospora, myceliophthora, trichoderma, aspergillus, penicillin, fusarium and the like; genes of the transporter include NCU10021 (HGT-1) and a homologous gene thereof as well as NCU04963 (HGT-2) and a homologous gene thereof; any one or two genes are knocked out, or bases of any one or two genes are mutated, or expression of any one or two genes is decreased. The engineering strain, which is obtained by importing the transporter into a microbial strain in an exogenous mode or by changing endogenous expression of the transporter, can gain or enhance a glucose transporting and utilizing capacity, and subsequently, a capacity of producing such bio-based chemicals as organic acid, organic alcohol and the like through fermentation can be gained or improved.

The invention relates to an Aspergillus niger gene engineering strain efficiently producing malic acid. The Aspergillus niger gene engineering strain is an Aspergillus niger gene engineering strain which knocks out a citric acid transporter gene cexA, and overexpresses a glucose transporter gene mstC, a hexokinase gene hxkA, a phosphofructokinase gene pfkA, and a pyruvate kinase gene pkiA which are derived from Aspergillus niger. The efficiency for producing malic acid of the Aspergillus niger gene engineering strain is significantly improved, the output on the eighth day through fed-batch fermentation in a fermentation tank reaches 195.72-210 g/L, a conversion rate of malic acid to glucose reaches 1.59-1.64 mol/mol, and a fermentation cycle is shorter by one day compared with a starting strain, namely the fermentation cycle is shortened from original 9 days to 8 days. An excellent strain for the preparation of malic acid by microbial fermentation methods is provided.

The invention belongs to the technical field of biology, relates to environment-sensitive tumor-targeting polymer micelle and a preparation method thereof, and especially relates to a cell microenvironment-sensitive oxidized ascorbic acid-modified tumor-targeting polymer micelle administration system and a preparation method thereof. An administration system realizes delivery in tumor by a glucose transporter mechanism, the polymer micelle of which the inner core has a disulfide bond crosslinked barrier is designed by use of the GSH characteristics of high density in the cell microenvironment, drug release characteristics trigged by the cell microenvironment are obtained, and the environment-sensitive tumor-targeting polymer micelle has a high transport capability, a fast transport rate and difficult saturation. Compared with polypeptide protein molecules, the environment-sensitive tumor-targeting polymer micelle has the characteristics of simple synthesis preparation, high stability and no immunogenicity. Through synergism of targeting and structure stabilization, drug delivery to a target position and a target cell is realized so that drug delivery efficiency is greatly improved and thus the environment-sensitive tumor-targeting polymer micelle has a good clinical application prospect.

The present invention provides an immediate release pharmaceutical formulation which includes a tablet or capsule formulation comprising metformin and the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin or its propylene glycol hydrate. The present invention also provides methods of preparing the formulations and methods of treating diseases or disorders associated with SGLT2 activity employing these formulations.

Most microalgae are obligate photoautotrophs and their growth is strictly dependent on the generation of photosynthetically-derived energy. In this study it is shown that the microalga Phaeodaclylurn tricornutum can be engineered to import glucose and grow in the dark through the introduction of genes encoding glucose transporters. Both the human and Chlorella kessleri glucose transporters facilitated the uptake of glucose by P. tricornutum, allowing the cells to metabolize exogenous organic carbon and thrive, independent of light. This is the first successful trophic conversion of an obligate photoautotroph through metabolic engineering, and it demonstrates that methods of cell nourishment can be fundamentally altered with the introduction of a single gene. Since strains transformed with the glucose transport genes are able to grow non-photosynthetically, they can be exploited for the analysis of photosynthetic processes through mutant generation and characterization. Finally, this work also represents critical progress toward large-scale commercial exploitation of obligate phototrophic algae through the use of microbial fermentation technology, eliminating significant limitations resulting from light-dependent growth.

The invention relates to C-aryl glucoside derivatives containing a difluoromethylene group. Specifically, the invention provides novel sodium-dependent glucose transporter (SGLT-2) inhibitors, a preparation method thereof and application thereof in preparing drugs for the treatment of diseases related to SGLT-2, especially diabetes, obesity and diabetic complications. The C-aryl glucoside derivatives provided by the invention have stronger inhibition activity and higher selectivity for sodium-dependent glucose transporter (SGLT-2), and can obviously promote the emission of glucose in urine of animals.

The invention relates to a glucopyranosyl derivative as a sodium-dependent glucose transporter (SGLT) inhibitor, a pharmaceutical composition containing the derivative and an application thereof in medicine, and in particular to the glucopyranosyl derivative as shown in a formula (I) or a pharmaceutically acceptable salt or all stereisomers thereof, or use of the pharmaceutical composition containing the derivative and the derivative and the pharmaceutical composition for preparing medicines treating diabetes and diabetes related diseases.

The invention relates to the field of medicines relevant to diabetes mellitus, in particular to a type 2 sodium galactose transporter [SGLT2 (sodium-dependent glucose transporter)] inhibitor of a C-glucoside type containing a cyclopropane structure, a preparation method of the type 2 sodium galactose transporter inhibitor, a medicinal composition containing the type 2 sodium galactose transporter inhibitor and application of the type 2 sodium galactose transporter inhibitor in terms of preparation of medicine for the diabetes mellitus. An R1 is one of H, F, Cl, Br, I, OR3, SR4, OCF3, CF3, CHF2, CH2F, alkyl of C1-C3 and a naphthenic base containing 3-5 carbon atoms, an R3 and an R4 are independently selected from alkyl of C1-C3, an R2 is selected from alkyl of C1-C3, cyclopropyl and OR5, and an R5 is one of alkyl of C1-C3 and cyclopropyl.

The present invention provides proteins having the Na⁺/glucose transporter activity, DNAs encoding the proteins, a method of screening for a compound enhancing or inhibiting the activity of the proteins, and compounds obtained by the screening method. The proteins having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, 15 or 26 are useful as a diagnostic marker for a disease such as diabetes. The compounds enhancing or inhibiting the activity of the proteins, obtained the screening method using the proteins, can be used as a prophylactic and/or therapeutic agent for a disease such as diabetes and hyperlipidemia.

The invention belongs to the technical field of medicine, and particularly relates to C-indican derivative as shown in general formula (I), the pharmaceutically acceptable salt of the C-indican derivative, the easily-hydrolyzed ester of the C-indican derivative, and the stereoisomer and the intermediate of the C-indican derivative. The invention specifically relates to the C-indican derivative taken as sodium-dependent glucose transporters (SGLT) inhibitor, the pharmaceutically acceptable salt of the C-indican derivative, the easily-hydrolyzed ester of the C-indican derivative, and the stereoisomer and the intermediate of the C-indican derivative. The C-indican derivative provided by the invention not only can be used for the diabetes mellitus such as the insulin dependent diabetes mellitus (I type diabetes mellitus), the non-insulin dependent diabetes mellitus (II type diabetes mellitus) and the like, but also can be used for the treatment and the prevention of various mellitus-related diseases such as the insulin-resistant disease and the fatness. R1, R2, R3, R4, R5, R6a, R6b, R6c, W, M, n and A are defined in the specification.

The present invention provides an agent that inhibits or promotes glucose uptake in the small intestine, etc., comprising a compound that inhibits or promotes the activity of Na⁺/glucose transporter (SGLT) homologs.

The invention discloses a chlorins glucoside compound, and a preparation method and application thereof, and belongs to the technical field of chemical medicines. According to the chlorins glucoside compound disclosed by the invention, through the selective combination of the glucose transport protein which is highly expressed on the surface of the tumor cells, the targeting effect of a photosensitizer and a sound-sensitive agent on tumor cells is improved. The in-vitro anti-tumor activity evaluation shows that compared with chlorins e6 which is used as a control, the chlorins glucoside compound provided by the invention has relatively high light activity and sound activity on humanhepatoma carcinoma cells Hep G2. The chlorins glucoside compound disclosed by the invention can be used for preparation of a photosensitizer and a sound-sensitive agent in photodynamic therapy and sonodynamics therapy methods for tumor therapy. According to the invention, the preparation process is simple, the reaction conditions are easy to control, and the production is facilitated.

The invention relates to a method for constructing recombinant escherichia coli. The method comprises the following steps: knocking out the coding gene lysC of aspartokinase, the coding gene panC of pantothenate synthetase and the coding gene ptsG of glucose transporter EIICBGlc in the escherichia coli; and overexpressing the panD gene with a PL promoter to obtain the recombinant escherichia coli. The invention further provides a method for producing beta-alanine by fermenting the recombinant escherichia coli constructed by the method. The recombinant escherichia coli constructed by the method is used for fed-batch fermentation in an improved inorganic salt culture medium, and has a yield of beta-alanine being 18.4g/L and a production strength being 0.61g/L.h, but the yield of beta-alanine of escherichia coli B0016-050 which is not improved by the method is only 5.2mg/L.

The invention relates to the field of medicines related to diabetes mellitus and particularly relates to a 2-type sodium-glucose co-transporter (SGLT2) inhibitor with a multi-aryl glucoside structure and shown as the specification, a preparation method thereof, a medicine composition taking the compound as an active components and an application thereof in preparing medicines for resisting diabetes mellitus.